Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

OncoImmunology

Volumn 6, Issue 9, 2017, Pages

  Kaderbhai, Courèche Guillaume ^a,b   Richard, Corentin ^b,c   Fumet, Jean David ^a,b   Aarnink, Anne ^a   Ortiz Cuaran, Sandra ^d   Pérol, Maurice ^d   Foucher, Pascal ^e   Coudert, Bruno ^a   Favier, Laure ^a   Lagrange, Aurélie ^a   Limagne, Emeric ^b,c   Boidot, Romain ^b,c   Ladoire, Sylvain ^a,b   Poudenx, Michel ^f   Ilie, Marius ^g,h   Hofman, Paul ^g,h   Saintigny, Pierre ^d   Ghiringhelli, François ^a,b,c  

^a Centre Anti Cancer GF Leclerc   (France)

^b Plateform Transfer in Biological Oncology   (France)

^c GIMI Genetic and Immunology Medical Institute   (France)

^d CENTRE LÉON BÉRARD   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

First line chemotherapy; nivolumab; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NIVOLUMAB; PACLITAXEL; PEMETREXED; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1;

ADENOCARCINOMA; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 85024401657     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1339856     Document Type: Article

References (42)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2):87-108; PMID:25651787
2. Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer:first-, second-, and third-line. Curr Oncol 2012; 19(Suppl 1):S52-58; PMID:22787411
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26(21):3543-51; PMID:18506025; https://doi.org/10.1200/JCO.2007.15.0375
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002; 346(2):92-8; PMID:11784875; https://doi.org/10.1056/NEJMoa011954
5. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14(10):1014-22; PMID:24048123; https://doi.org/10.1038/ni.2703
6. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting:integrating immunity's roles in cancer suppression and promotion. Science 2011; 331(6024):1565-70; PMID:21436444; https://doi.org/10.1126/science.1203486
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting:from immunosurveillance to tumor escape. Nat Immunol 2002; 3(11):991-8; PMID:12407406; https://doi.org/10.1038/ni1102-991
8. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Ann Rev Immunol 2011; 29:235-71; PMID:21219185; https://doi.org/10.1146/annurev-immunol-031210-101324
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID:22437870; https://doi.org/10.1038/nrc3239
10. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Eng J Med 2015; 373(17):1627-39; PMID:26412456; https://doi.org/10.1056/NEJMoa1507643
11. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med 2015; 373(2):123-35; PMID:26028407; https://doi.org/10.1056/NEJMoa1504627
12. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade:a common denominator approach to cancer therapy. Cancer Cell 2015; 27(4):450-61; PMID:25858804; https://doi.org/10.1016/j.ccell.2015.03.001
13. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer:current status and future direction. Cancer J 2014; 20(4):281-9; https://doi.org/10.1097/PPO.0000000000000063
14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 2012; 366(26):2455-65; PMID:22658128; https://doi.org/10.1056/NEJMoa1200694
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012; 366(26):2443-54; PMID:22658127; https://doi.org/10.1056/NEJMoa1200690
16. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528):563-7; PMID:25428504; https://doi.org/10.1038/nature14011
17. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017; 17(2):97-111; PMID:27748397; https://doi.org/10.1038/nri.2016.107
18. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy:a prognostic score from individual data of nine randomised trials. Euro J Cancer 2010; 46(4):735-43; PMID:20045311; https://doi.org/10.1016/j.ejca.2009.12.013
19. Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1-Update and clarification:From the RECIST committee. Euro J Cancer 2016; 62:132-7; PMID:27189322; https://doi.org/10.1016/j.ejca.2016.03.081
20. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet 2016; 387(10027):1540-50; PMID:26712084; https://doi.org/10.1016/S0140-6736(15)01281-7
21. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387(10030):1837-46; PMID:26970723; https://doi.org/10.1016/S0140-6736(16)00587-0
22. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Eng J Med 2016; 375(19):1823-33; PMID:27718847; https://doi.org/10.1056/NEJMoa1606774
23. Shien K, Papadimitrakopoulou VA, Wistuba, II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 2016; 99:79-87; PMID:27565919; https://doi.org/10.1016/j.lungcan.2016.06.016
24. Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer:truth or fiction? J Immunother Cancer 2016; 4:48
25. Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies:A systematic review and meta-analysis. Crit Rev Oncol Hematol 2016; 100:88-98; PMID:26895815; https://doi.org/10.1016/j.critrevonc.2016.02.001
26. Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba, II, Hirsch FR, Committee IP. Programmed death-ligand 1 immunohistochemistry in lung cancer:in what state is this art? J Thoracic Oncol 2015; 10(7):985-9
27. Zhong Z, Sanchez-Lopez E, Karin M. Autophagy, inflammation, and immunity:A troika governing cancer and its treatment. Cell 2016; 166(2):288-98; PMID:27419869; https://doi.org/10.1016/j.cell.2016.05.051
28. Luo M, Fu L. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis:some chemotherapeutical drugs may finally work through immune response. Oncotarget 2016; 7(20):29794-803; PMID:26919108
29. Garg AD, Romano E, Rufo N, Agostinis P. Immunogenic versus tolerogenic phagocytosis during anticancer therapy:mechanisms and clinical translation. Cell Death Differ 2016; 23(6):938-51; PMID:26891691; https://doi.org/10.1038/cdd.2016.5
30. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 2015; 28(6):690-714; PMID:26678337; https://doi.org/10.1016/j.ccell.2015.10.012
31. Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016; 44(2):343-54; PMID:26872698; https://doi.org/10.1016/j.immuni.2015.11.024
32. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30(10):1147-58; PMID:21151176; https://doi.org/10.1038/onc.2010.500
33. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways:the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 2014; 20(11):2831-7; PMID:24879823; https://doi.org/10.1158/1078-0432.CCR-13-3141
34. Gujar SA, Clements D, Lee PW. Two is better than one:Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3(1):e27622; PMID:24804161; https://doi.org/10.4161/onci.27622
35. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70(8):3052-61; PMID:20388795; https://doi.org/10.1158/0008-5472.CAN-09-3690
36. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19(1):57-64; PMID:23202296; https://doi.org/10.1038/nm.2999
37. Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH, Jr, Bagala C, Colombi F, Cagnazzo C, Gioeni L, Wang E, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol 2014; 25(9):1750-5; https://doi.org/10.1093/annonc/mdu205
38. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280):1463-9; PMID:26940869; https://doi.org/10.1126/science.aaf1490
39. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350(6257):207-11; PMID:26359337; https://doi.org/10.1126/science.aad0095
40. Braun DA, Burke KP, Van Allen EM. Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res 2016; 22(23):5642-50; PMID:27698000; https://doi.org/10.1158/1078-0432.CCR-16-0066
41. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-8; PMID:25765070; https://doi.org/10.1126/science.aaa1348
42. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Eng J Med 2015; 372(26):2509-20; PMID:26028255; https://doi.org/10.1056/NEJMoa1500596